Safety pharmacology--current and emerging concepts

Area of Science:

• Pharmacology
• Drug Development
• Toxicology

Background:

• Safety pharmacology (SP) is crucial for predicting adverse effects of new chemical entities (NCEs) before human testing.
• International Conference on Harmonisation (ICH) S7A and S7B guidelines define core battery and supplemental SP studies.
• These studies assess effects on major organ systems at therapeutic and supra-therapeutic exposures.

Purpose of the Study:

• To review current practices in safety pharmacology.
• To outline emerging concepts and newer approaches in SP studies.
• To discuss the integration of these advancements for enhanced drug safety evaluation.

Main Methods:

• Review of existing literature and guidelines (ICH S7A, S7B).
• Analysis of current methodologies in safety pharmacology.
• Exploration of novel approaches such as frontloading and parallel assessments.
• Consideration of non-standard species, biomarkers, and integrated toxicology/SP assessments.

Main Results:

• Current SP practices involve core battery and supplemental studies on major organ systems.
• Emerging concepts include frontloading SP, parallel assessment of core battery studies, and use of non-standard species.
• Biomarkers and combined toxicology/SP assessments are being explored to refine safety evaluations.

Conclusions:

• Integrating newer approaches can significantly enhance the scope and depth of safety pharmacology.
• These advancements provide refined mechanistic insights into potential adverse effects of test compounds.
• Enhanced SP studies contribute to more robust drug development and improved patient safety.